Nov 4, 2021 5:00 pm EDT Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
Oct 28, 2021 7:00 am EDT DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
Oct 26, 2021 7:00 am EDT New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting
Oct 25, 2021 7:00 am EDT Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
Oct 22, 2021 7:00 am EDT Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
Sep 28, 2021 7:00 am EDT Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week
Sep 16, 2021 7:00 am EDT Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma
Aug 30, 2021 7:00 am EDT Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
